13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001389933
Total reported value
$524.4M
$524.4M
84 檔
25.3%
At the close of Q3 2024, DAFNA Capital Management LLC disclosed equity holdings valued at approximately $524.4M, spread across 84 reported holdings.
DAFNA Capital Management LLC executed strategic sector rebalancing during Q3 2024, establishing 6 new positions while fully exiting 5 holdings and trimming 26 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.37% | -3.32% | -9.78% | |
| 2 | STXS | Stereotaxis Inc | Stock-Other | 6.59% | -1.24% | — | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.55% | +7.24% | +1.19% | |
| 4 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.97% | -0.47% | — | |
| 5 | ✓ | Merus N V | Stock-Other | 4.87% | — | +0.76% | |
| 6 | ATRC | Atricure Inc | Stock-Other | 4.25% | -0.69% | +0.39% | |
| 7 | IDYA | Ideaya Biosciences Inc | Stock-Other | 3.53% | -0.08% | +11.65% | |
| 8 | IBB | Ishares Biotechnology ETF | ETF-Tech | 3.53% | -0.85% | — | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 3.16% | -1.21% | EXIT | |
| 10 | AXGN | Axogen Inc | Stock-Other | 3.10% | -0.04% | — | |
| 11 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.66% | — | +16.23% | |
| 12 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.55% | -0.43% | — | |
| 13 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.47% | -4.77% | EXIT | |
| 14 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.40% | +0.24% | -19.84% | |
| 15 | BHVN | Biohaven Ltd. | Stock-Other | 2.21% | -1.24% | -14.45% | |
| 16 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 2.05% | -0.53% | — | |
| 17 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.98% | -1.22% | EXIT | |
| 18 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.89% | -0.26% | -2.79% | |
| 19 | KURA | Kura Oncology Inc | Stock-Other | 1.89% | -0.19% | -3.57% | |
| 20 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.88% | — | -33.58% | |
| 21 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.44% | +0.96% | -21.47% | |
| 22 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.38% | — | -2.15% | |
| 23 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.20% | -0.17% | -5.32% | |
| 24 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.11% | -1.35% | EXIT | |
| 25 | DXCM | Dexcom Inc | Stock-Healthcare | 1.04% | -0.12% | — | |
| 26 | KROS | Keros Therapeutics Inc | Stock-Other | 1.01% | — | +8.86% | |
| 27 | ALEC | Alector Inc | Stock-Other | 1.00% | -0.09% | — | |
| 28 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.93% | +0.42% | +1.38% | |
| 29 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.89% | -0.15% | — | |
| 30 | PODD | Insulet CORP | Stock-Healthcare | 0.87% | +1.28% | — | |
| 31 | ALKS | Alkermes plc | Stock-Healthcare | 0.80% | -0.11% | — | |
| 32 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.76% | -0.91% | -22.77% | |
| 33 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.73% | — | -0.57% | |
| 34 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.70% | — | -40.04% | |
| 35 | ✓ | Acelyrin Inc | Stock-Other | 0.70% | — | -13.08% | |
| 36 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.69% | +0.03% | +73.54% | |
| 37 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.69% | +0.16% | +11.24% | |
| 38 | IPSC | Century Therapeutics Inc | Stock-Other | 0.69% | -0.13% | — | |
| 39 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.66% | — | -7.29% | |
| 40 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.65% | -0.02% | — | |
| 41 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.60% | -0.15% | — | |
| 42 | BWAY | Brainsway Ltd-adr | Stock-Other | 0.55% | — | -15.56% | |
| 43 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.54% | -0.16% | — | |
| 44 | ARAY | Accuray Inc | Stock-Other | 0.52% | -0.07% | — | |
| 45 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.51% | — | -38.00% | |
| 46 | INGN | Inogen Inc | Stock-Other | 0.48% | -0.15% | — | |
| 47 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.45% | — | -2.06% | |
| 48 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.42% | -0.01% | +23.11% | |
| 49 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.42% | -0.01% | +40.38% | |
| 50 | ✓ | Immatics NV | Stock-Other | 0.39% | -0.28% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AXGN | Axogen Inc | +1.5% | — | Unchanged |
| 2 | RVMD | Revolution Medicines Inc | +0.8% | +1.19% | Add |
| 3 | ATRC | Atricure Inc | +0.8% | +0.39% | Add |
| 4 | STXS | Stereotaxis Inc | +0.6% | — | Unchanged |
| 5 | LXEO | Lexeo Therapeutics Inc | +0.5% | NEW | New buy |
| 6 | ASND | Ascendis Pharma A/S | +0.5% | +10.62% | Add |
| 7 | BHVN | Biohaven Ltd. | +0.4% | -14.45% | Trim |
| 8 | AQST | Aquestive Therapeutics Inc | +0.4% | +11.24% | Add |
| 9 | ALLO | Allogene Therapeutics Inc | +0.4% | +73.54% | Add |
| 10 | GPCR | Structure Therapeutics Inc | +0.3% | +580.00% | Add |
| 11 | DAWNGBX | Day One Biopharmaceuticals I | +0.3% | +12.59% | Add |
| 12 | KROS | Keros Therapeutics Inc | +0.3% | +8.86% | Add |
| 13 | BNTX | Biontech Se-adr | +0.2% | NEW | New buy |
| 14 | EWTX | Edgewise Therapeutics Inc | +0.2% | -21.47% | Trim |
| 15 | 260 | Centessa Pharmaceuticals-adr | +0.2% | -2.06% | Trim |
| 16 | CATX | Perspective Therapeutics Inc | +0.2% | -0.57% | Trim |
| 17 | IBB | Ishares Biotechnology ETF | +0.2% | — | Unchanged |
| 18 | BCRX | Biocryst Pharmaceuticals Inc | +0.2% | -5.32% | Trim |
| 19 | GRAL | Grail Inc | +0.2% | NEW | New buy |
| 20 | AUTL | Autolus Therapeutics PLC | +0.1% | +40.38% | Add |
| 21 | BDTX | Black Diamond Therapeutics I | +0.1% | NEW | New buy |
| 22 | LKFT | Lakefront Biotherapeutic-adr | +0.1% | — | Unchanged |
| 23 | BWAY | Brainsway Ltd-adr | +0.1% | -15.56% | Trim |
| 24 | PODD | Insulet CORP | +0.1% | — | Unchanged |
| 25 | ALKS | Alkermes plc | +0.1% | — | Unchanged |
| 26 | ✓ | +0.1% | NEW | New buy | |
| 27 | VSTM | Verastem Inc | +0.1% | NEW | New buy |
| 28 | MLYS | Mineralys Therapeutics Inc | +0.1% | +23.11% | Add |
| 29 | TNDM | Tandem Diabetes Care Inc | +0.1% | — | Unchanged |
| 30 | INGN | Inogen Inc | +0.1% | — | Unchanged |
| 31 | CATBUSD | Astria Therapeutics Inc | +0.1% | -7.29% | Trim |
| 32 | BCYC | Bicycle Therapeutics Plc-adr | +0.1% | — | Unchanged |
| 33 | ✓ | Nyxoah S A | +0.1% | — | Unchanged |
| 34 | ✓ | Polypid LTD | +0.1% | +66.89% | Add |
| 35 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | +0.1% | — | Unchanged |
| 36 | IMVT | Immunovant Inc | +0.1% | +8.51% | Add |
| 37 | STRO | Sutro Biopharma, Inc. | 0% | — | Unchanged |
| 38 | ✓ | Proqr Therapeutics N.v. | 0% | — | Unchanged |
| 39 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 40 | GOSS | Gossamer Bio Inc | 0% | +0.71% | Add |
| 41 | SPRY | Ars Pharmaceuticals Inc | 0% | -38.00% | Trim |
| 42 | FHTX | Foghorn Therapeutics Inc | 0% | -10.00% | Trim |
| 43 | CMPX | Compass Therapeutics Inc | 0% | — | Unchanged |
| 44 | ACRV | Acrivon Therapeutics Inc | 0% | -7.36% | Trim |
| 45 | ALEC | Alector Inc | 0% | — | Unchanged |
| 46 | RCUS | Arcus Biosciences Inc | 0% | +1.38% | Add |
| 47 | CMPS | Compass Pathways PLC | 0% | — | Unchanged |
| 48 | XENE | Xenon Pharmaceuticals Inc | — | — | Unchanged |
| 49 | ✓ | Compugen LTD | — | -3.25% | Trim |
| 50 | MASI* | Masimo CORP | — | — | Unchanged |
According to official SEC Form 13F filings, DAFNA Capital Management LLC reported a total U.S. public equity portfolio value of $524.4M across 84 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, STXS, RVMD) accounted for 25.3% of total reported equity market value during Q3 2024.
Top New Position Initiated
LXEO
市值: $2.3M
Top Position Liquidated / Trimmed
MORFUSD
前期市值: $7.9M
During Q3 2024, DAFNA Capital Management LLC's top holdings by market value included XBI (9.4%)、STXS (6.6%)、RVMD (5.5%). The largest single position, XBI, represented 9.4% of total portfolio value.
In Q3 2024, DAFNA Capital Management LLC made 56 total portfolio adjustments, initiating 6 new buys, adding to 19 positions, trimming 26 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.